91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
91黑料 CEO Dr. Steve Cutler discusses clinical research as one of Ireland’s most promising industries in this special supplement on Ireland’s economy that appeared in the weekend edition of the New York Times.
-
Nuala Murphy contributes to the Bottom Line BBC4 podcast about the impact of the COVID-19 vaccine on the clinical trial process and whether these changes could work for other drugs.
-
How data flows in cell therapy studies differ from other studies and strategies to manage the high volume of data in CGT trials is highlighted in this .
-
In this , Dr. Peter Schueler, Senior VP Drug Development Services, Neurosciences at 91黑料, talks about topics discussed in a timely new book he edited titled Innovation in Clinical Trial Methodologies.
-
Seth Nelson, Senior Director of Patient Recruitment and Clinical Research Services, provides expert commentary on .
-
91黑料’s Tamie Joeckel and Brandon Fletcher take us through .
-
91黑料 CEO Steve Cutler discusses how the research industry has changed in the past year, concluding that decentralised models are helping to improve patient outcomes and bring treatments to market faster ().
-
around the key components of decentralised trials and steps of deployment.
-
Dr. Brian Huber, VP Drug Development & Consulting, discusses the shift from histology-based to lesion-based trial design in precision medicine
-
.jpg?w=545&itok=Rwqj2ePn "IPT discussed in technical publications.")
Greg Cox, Director 91黑料 Laboratory Services, shares his perspective on how integrating digital pathology into clinical trials can benefit study outcomes and data integrity.
.jpg?w=340&itok=xrpB93pQ "IPT discussed in technical publications."){kind=icon}